BTAI - BioXcel Therapeutics, Inc.
1.06
-0.040 -3.774%
Share volume: 478,875
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.10
-0.04
-0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-06-2024 | 11-14-2024 | 03-28-2025 | 05-12-2025 | 08-12-2025 | 11-12-2025 | 03-27-2026 | |
| Assets | |||||||||
| Total Assets | 82.323 M | 65.435 M | 48.892 M | 38.338 M | 38.566 M | 25.789 M | 44.792 M | 44.916 M | |
| Current Assets | 80.917 M | 64.181 M | 47.792 M | 37.394 M | 37.777 M | 25.243 M | 44.403 M | 44.685 M | |
| Inventories | 2.439 M | 2.680 M | 1.525 M | 679.000 K | 642.000 K | 506.000 K | 459.000 K | 722.000 K | |
| Other Current Assets | 1.856 M | 1.643 M | 1.398 M | 1.440 M | 1.385 M | 995.000 K | 934.000 K | 10.945 M | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 74.141 M | 56.271 M | 40.387 M | 29.854 M | 31.013 M | 17.435 M | 36.176 M | 28.415 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 706.000 K | 629.000 K | 552.000 K | 475.000 K | 399.000 K | 324.000 K | 249.000 K | 175.000 K | |
| Other Assets | 700.000 K | 625.000 K | 548.000 K | 469.000 K | 390.000 K | 222.000 K | 140.000 K | 56.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 82.323 M | 65.435 M | 48.892 M | 38.338 M | 38.566 M | 25.789 M | 44.792 M | 44.916 M | |
| Total liabilities | 154.686 M | 139.736 M | 134.525 M | 131.439 M | 128.738 M | 133.456 M | 133.711 M | 140.379 M | |
| Total current liabilities | 31.481 M | 27.288 M | 25.557 M | 22.233 M | 25.546 M | 33.376 M | 37.804 M | 53.926 M | |
| Accounts Payable | 17.220 M | 13.256 M | 14.889 M | 15.990 M | 15.450 M | 16.692 M | 16.276 M | 14.701 M | |
| Other liabilities | 21.572 M | 9.442 M | 4.528 M | 6.698 M | 3.274 M | 2.611 M | 3.605 M | 1.790 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 101.633 M | 103.006 M | 104.440 M | 102.508 M | 99.918 M | 97.469 M | 92.302 M | 84.663 M | |
| Other liabilities | 21.572 M | 9.442 M | 4.528 M | 6.698 M | 3.274 M | 2.611 M | 3.605 M | 1.790 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -72.363 M | -74.301 M | -85.633 M | -93.101 M | -90.172 M | -107.667 M | -88.919 M | -95.463 M | |
| Common stock | 545.026 M | 551.387 M | 553.705 M | 557.096 M | 567.279 M | 568.971 M | 618.630 M | 624.631 M | |
| Retained earnings | -617.389 M | -625.688 M | -639.338 M | -650.197 M | -657.451 M | -676.638 M | -707.549 M | -720.094 M |